Neoadjuvant trial of Pre-operative Exemestane or Letrozole +/- Celecoxib in the treatment of ER + postmenopausal early breast cancer

NEO-EXCEL  is a Phase III, multicentre, randomised controlled trial in postmenopausal women with ER + early breast cancer. The primary objective of the trial is to determine whether the addition of a COX-2 inhibitor to a 16 week treatment regimen of exemestane or letrozole results in a greater clinical response. The Breast Cancer Clinical Trials Team at St. Margaret's Hospital, Epping and PAH, Harlow are recruiting patients into this trial. Details about this trial are at CancerHelp UK or by telephone 01279 827396.